TITLE

Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors

AUTHOR(S)
Wolanskyj, Alexandra P.; Schwager, Susan M.; Mcclure, Rebecca F.; Larson, Dirk R.; Tefferi, Ayalew
PUB. DATE
February 2006
SOURCE
Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p159
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To describe the long-term natural history of essential thrombocythemia (ET) in terms of life expectancy, risk of disease transformation into a more aggressive myeloid disorder, and prognostic factors for both survival and disease complications. PATIENTS AND METHODS: The study population consisted of a consecutive cohort of patients seen at the Mayo Clinic in Rochester, Minn, in whom a diagnosis of ET was established before 1992, thus allowing a minimum of 10 years of potential follow-up. The conventional criteria-based diagnosis was confirmed by bone marrow biopsy in all instances. RESULTS: A total of 322 patients were studied (median age, 54 years; median follow-up, 13.6 years). With a median survival time of 18.9 years, survival in the first decade of disease was similar to that of the control population (risk ratio, 0.72; 95% confidence interval, 0.50–0.99) but became significantly worse thereafter (risk ratio, 2.21; 95% confidence interval, 1.74–2.76). Multivariable analysts Identified age at diagnosis of 60 years or older, leukocytosis, tobacco use, and diabetes mellitus as Independent predictors of poor survival. A 2-variable model based on an age cutoff of 60 years and leukocyte count of 15 × 109/L resulted in 3 risk groups with significant difference in survival. In addition, age at diagnosis of 60 years or older, leukocytosis, and history of thrombosis were independent predictors of major thrombotic events. The risk of leukemic or any myeloid disease transformation was low in the first 10 years (1.4% and 9.1%, respectively) but increased substantially in the second (8.1% and 28.3%, respectively) and third (24.0% and 58.5%, respectively) decades of the disease. CONCLUSION: Life expectancy in patients with ET is significantly worse than that of the control population. Leukocytosis is identified as a novel independent risk factor for both inferior survival and thrombotic events.
ACCESSION #
19787391

 

Related Articles

  • The Long-term Outlook for Essential Thrombocythemia. Campbell, Peter J.; Green, Anthony R. // Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p157 

    The article discusses the importance of studies on long-term consequences of essential thrombocythemia (ET), a myeloproliferative disorders. Such studies could provide diagnostic work-up and management approaches, comprehensive and complete clinical follow-up, and standardized end point...

  • Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Hong, Y.; Wang, G.; del Arroyo, A. Gutierrez; Hernandez, J.; Skene, C.; Erusalimsky, J. D. // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1117 

    Anagrelide (ANA) and hydroxycarbamide (HC) are two distinct pharmacological agents used to treat thrombocythaemia associated with myeloproliferative disorders. Although both drugs have been in clinical use for a number of years, comparative studies of their selectivity and mode of action are...

  • Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán, A.; Cervantes, F.; Bellosillo, B.; Giralt, M.; Juliá, A.; Hernández-Boluda, J. C.; Bosch, A.; Hernández-Nieto, L.; Clapés, V.; Burgaleta, C.; Salvador, C.; Arellano-Rodrigo, E.; Colomer, D.; Besses, C. // Leukemia (08876924);Jun2007, Vol. 21 Issue 6, p1218 

    The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range:...

  • Bone metabolism during interferon-alpha treatment of essential thrombocythemia. Kusec, Rajko; Kusec, Vesna; Gisslinger, Bettina; Woloszczuk, Wolfgang; Gisslinger, Heinz // Wiener Klinische Wochenschrift;2004, Vol. 116 Issue 1/2, p37 

    In-vitro studies have demonstrated that interferon (IFN) has an inhibitory effect on bone formation. Changes in bone metabolism were investigated in 19 patients treated for essential thrombocythemia with IFN-alpha. Serum biochemical parameters of bone remodeling [total alkaline phosphatase,...

  • Myeloproliferative disorders: complications, survival and causes of death. Brodmann, S.; Passweg, J. R.; Gratwohl, A.; Tichelli, A.; Skoda, R. C. // Annals of Hematology;Jun2000, Vol. 79 Issue 6, p312 

    This retrospective single-center study compared thromboembolic and hemorrhagic complications, survival and causes of death in a cohort of 102 consecutive patients with myeloproliferative disorders (MPD). We included 17 patients with essential thrombocythemia (ET), 59 with polycythemia vera (PV),...

  • Long-term management of thrombocytosis in essential thrombocythaemia. Birgegård, Gunnar // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p1 

    Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder with a prolonged clinical course and a near-normal life expectancy. Therapy is stratified according to risk of thrombohaemorrhagic events. In high-risk patients, platelet reduction is generally recommended. In...

  • Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Magnus Hultdin; Gunnel Sundström; Anders Wahlin; Berith Lundström; Jan Samuelsson; Gunnar Birgegård; Anna Engström-Laurent // Medical Oncology;Jan2007, Vol. 24 Issue 1, p63 

    Abstract  Anagrelide is a second-line option for reduction of thrombocythemia in patients with chronic myeloproliferative disorders (CMPDs). A multicenter, open, phase II study of anagrelide treatment in 60 patients during 2 yr was performed by the Swedish Myeloproliferative Disorder Study...

  • Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations. Higgs, J. R.; Sadek, I.; Neumann, P. E.; Ing, V. W.; Renault, N. K.; Berman, J. N.; Greer, W. L. // Leukemia (08876924);Aug2008, Vol. 22 Issue 8, p1551 

    Essential thrombocythemia (ET) is a chronic myeloproliferative disorder, characterized by increased proliferation of megakaryocytes and elevated platelet count that usually occurs sporadically. We report a family with seven affected individuals in three generations, including one individual with...

  • Epstein-Barr Virus Infection Associated With Bone Marrow Fibrin-Ring Granuloma. Hee-Jung Chung // American Journal of Clinical Pathology;Feb2010, Vol. 133 Issue 2, p300 

    We previously reported 24 cases of marrow fibrin-ring granuloma (FRG) encountered in 1 institution and concluded that, contrary to previous studies showing marrow FRG as a diagnostic marker for Q fever, Epstein-Barr virus (EBV) was the most common proven cause of such FRG. The present study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics